Coaching Scorecards

Back to Scorecards

James Patel

MSL

Interaction INT-007 · Mar 4, 2026

Overall Score

79/100
Score Overview
Opening & RapportClinical KnowledgeNeeds AssessmentObjection HandlingCompliance & RegulatoryClosing & Next StepsEmpathy & Communication

Rubric Breakdown

Opening & Rapport

4/5

Observation

Professional opening that demonstrated awareness of the HCP's prior questions and set the scientific context.

Suggestion

Consider exploring the HCP's clinical context more before diving into data.

Evidence

[00:00]“I understand you had some questions about Veloratine's cardiovascular outcome da...”

Clinical Knowledge

4/5

Observation

Strong knowledge of CV outcomes data with appropriate statistical rigor. However, ventured into speculative territory regarding HFpEF benefits.

Suggestion

Limit discussion to published data and approved labeling. When discussing investigational areas, clearly frame as hypothesis-generating.

Evidence

[00:40]“The primary composite endpoint of cardiovascular death, MI, and stroke showed a ...”

Needs Assessment

3/5

Observation

Understood the HCP's role as a heart failure specialist but did not deeply explore their specific practice patterns or research interests.

Suggestion

Ask about the HCP's current approach to hypertension management in their HF patients before presenting data.

Evidence

[00:18]“I'm a heart failure specialist, and several of my hypertension colleagues have b...”

Objection Handling

4/5

Observation

Handled questions about statistical power transparently and provided accurate drug interaction information.

Suggestion

Apply the same transparency to all claims, including mechanistic ones about potential benefits.

Evidence

[01:35]“The study was only powered for the composite endpoint. The individual components...”

Compliance & Regulatory

3/5

Observation

Made unsupported claims about potential cardioprotective effects and HFpEF benefits not in approved labeling. The phrase 'we believe' implies company endorsement of unproven benefits.

Suggestion

Restrict discussion to published, peer-reviewed data. If discussing investigational areas, clearly state the data is preliminary and not part of approved labeling.

Evidence

[02:20]“Based on the mechanism of action, we believe Veloratine could have direct cardio...”

Closing & Next Steps

4/5

Observation

Established clear follow-up around interim trial data and provided publication references.

Suggestion

Set a more specific timeline for the follow-up rather than a general 'mid-year' estimate.

Evidence

[05:30]“I expect interim data around mid-year. I'll reach out as soon as the results are...”

Empathy & Communication

4/5

Observation

Communicated at an appropriate scientific level for a specialist. Showed enthusiasm for the science without being promotional.

Suggestion

Channel enthusiasm into the data rather than into speculative claims about potential benefits.

Evidence

[04:05]“The cardiovascular outcomes data was published in the New England Journal last y...”
Coaching Focus Areas
1
On-Label Scientific Communication

Must distinguish clearly between approved labeling claims, published data, and mechanistic hypotheses. Avoid implying company beliefs about unapproved benefits.

Target: When discussing investigational areas, preface with 'While not part of the current approved labeling, published data from [source] shows...' rather than 'we believe.'

2
Post-Hoc Analysis Communication

Strengthen framing of exploratory and post-hoc analyses to avoid overstating their significance.

Target: Always note sample size, power limitations, and hypothesis-generating nature when discussing post-hoc or subgroup analyses.

3
Practice Pattern Exploration

Develop more robust needs assessment for specialist HCPs to better contextualize data presentation.

Target: Ask about the HCP's patient demographics, treatment protocols, and key clinical decision factors before presenting data.